These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. Crosignani S; Page P; Missotten M; Colovray V; Cleva C; Arrighi JF; Atherall J; Macritchie J; Martin T; Humbert Y; Gaudet M; Pupowicz D; Maio M; Pittet PA; Golzio L; Giachetti C; Rocha C; Bernardinelli G; Filinchuk Y; Scheer A; Schwarz MK; Chollet A J Med Chem; 2008 Apr; 51(7):2227-43. PubMed ID: 18318469 [TBL] [Abstract][Full Text] [Related]
27. Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the carboxamide group. Kemnitzer W; Sirisoma N; Nguyen B; Jiang S; Kasibhatla S; Crogan-Grundy C; Tseng B; Drewe J; Cai SX Bioorg Med Chem Lett; 2009 Jun; 19(11):3045-9. PubMed ID: 19394823 [TBL] [Abstract][Full Text] [Related]
28. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases. Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745 [TBL] [Abstract][Full Text] [Related]
29. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Yamaguchi T; Tomishima Y; Futaki N; Toda Y; Saito S Bioorg Med Chem; 2008 Feb; 16(3):1111-24. PubMed ID: 18006322 [TBL] [Abstract][Full Text] [Related]
30. Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis. Rosen MD; Hack MD; Allison BD; Phuong VK; Woods CR; Morton MF; Prendergast CE; Barrett TD; Schubert C; Li L; Wu X; Wu J; Freedman JM; Shankley NP; Rabinowitz MH Bioorg Med Chem; 2008 Apr; 16(7):3917-25. PubMed ID: 18289861 [TBL] [Abstract][Full Text] [Related]
34. Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay. Meng T; Su HR; Binkert C; Fischli W; Zhou L; Shen JK; Wang MW Acta Pharmacol Sin; 2008 Apr; 29(4):517-27. PubMed ID: 18358099 [TBL] [Abstract][Full Text] [Related]
35. Preparation and optimization of a series of 3-carboxamido-5-phenacylaminopyrazole bradykinin B1 receptor antagonists. Dressen D; Garofalo AW; Hawkinson J; Hom D; Jagodzinski J; Marugg JL; Neitzel ML; Pleiss MA; Szoke B; Tung JS; Wone DW; Wu J; Zhang H J Med Chem; 2007 Oct; 50(21):5161-7. PubMed ID: 17880055 [TBL] [Abstract][Full Text] [Related]
36. Parasympathetic non-adrenergic, non-cholinergic transmission in rat parotid glands: effects of cholecystokinin-A and -B receptor antagonists on the secretory response. Ekström J; Cevik Aras H Regul Pept; 2008 Feb; 146(1-3):278-84. PubMed ID: 18006087 [TBL] [Abstract][Full Text] [Related]
37. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands. Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817 [TBL] [Abstract][Full Text] [Related]
38. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2. DiMauro EF; Buchanan JL; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Janosky B; Lee JH; Li X; Martin MW; Tomlinson SA; White RD; Zheng XM; Patel VF; Fremeau RT Bioorg Med Chem Lett; 2008 Aug; 18(15):4267-74. PubMed ID: 18640038 [TBL] [Abstract][Full Text] [Related]
39. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. Wittman MD; Carboni JM; Yang Z; Lee FY; Antman M; Attar R; Balimane P; Chang C; Chen C; Discenza L; Frennesson D; Gottardis MM; Greer A; Hurlburt W; Johnson W; Langley DR; Li A; Li J; Liu P; Mastalerz H; Mathur A; Menard K; Patel K; Sack J; Sang X; Saulnier M; Smith D; Stefanski K; Trainor G; Velaparthi U; Zhang G; Zimmermann K; Vyas DM J Med Chem; 2009 Dec; 52(23):7360-3. PubMed ID: 19778024 [TBL] [Abstract][Full Text] [Related]
40. Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. Dow RL; Carpino PA; Hadcock JR; Black SC; Iredale PA; DaSilva-Jardine P; Schneider SR; Paight ES; Griffith DA; Scott DO; O'Connor RE; Nduaka CI J Med Chem; 2009 May; 52(9):2652-5. PubMed ID: 19351113 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]